184 related articles for article (PubMed ID: 35157055)
1. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
Weintraub WS; Bhatt DL; Zhang Z; Dolman S; Boden WE; Bress AP; King JB; Bellows BK; Tajeu GS; Derington CG; Johnson J; Andrade K; Steg PG; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Kolm P
JAMA Netw Open; 2022 Feb; 5(2):e2148172. PubMed ID: 35157055
[TBL] [Abstract][Full Text] [Related]
2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States.
Weintraub WS; Bhatt DL; Zhang Z; Dolman S; Boden WE; Bress AP; Bellows BK; Derington CG; Philip S; Steg G; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Kolm P
J Am Heart Assoc; 2024 Jan; 13(1):e032413. PubMed ID: 38156550
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.
Lachaine J; Charron JN; Gregoire JC; Hegele RA; Leiter LA
Clinicoecon Outcomes Res; 2023; 15():295-308. PubMed ID: 37101608
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
Gao L; Moodie M; Li SC
Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
[TBL] [Abstract][Full Text] [Related]
10. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ; Bhatt DL; Kinninger A; Lakshmanan S; Muhlestein JB; Le VT; May HT; Shaikh K; Shekar C; Roy SK; Tayek J; Nelson JR
Eur Heart J; 2020 Oct; 41(40):3925-3932. PubMed ID: 32860032
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
12. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
13. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
Arbel R; Aboalhasan E; Hammerman A; Azuri J
Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273
[TBL] [Abstract][Full Text] [Related]
14. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
15. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
16. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
18. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.
Spahillari A; Zhu J; Ferket BS; Hunink MGM; Carr JJ; Terry JG; Nelson C; Mwasongwe S; Mentz RJ; O'Brien EC; Correa A; Shah RV; Murthy VL; Pandya A
JAMA Cardiol; 2020 Aug; 5(8):871-880. PubMed ID: 32401264
[TBL] [Abstract][Full Text] [Related]
20. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
